Pentagon Expands Medical Support, But Gender Equity and Science Still Lacking in Testosterone Policy
Select a version of the text written from a presumed ideological perspective. This is not the original text, but a hypothetical version — how someone with that viewpoint might have phrased it. Tapping the current version again will return to the original or select cleaned version.
The Defense Department will screen service members for low testosterone and offer hormone therapy, claiming readiness concerns. Critics highlight the lack of scientific transparency and the ongoing gender inequity in military health policy.
The Pentagon has announced it will begin testing active-duty troops for low testosterone levels and, when deemed appropriate, offer hormone replacement therapy. Officials claim this measure is designed to keep service members 'strong, resilient and capable,' and to support 'maximum psychological and mental readiness' on modern battlefields. However, this move raises serious questions about the military’s priorities and commitment to evidence-based, equitable healthcare.
The policy comes in the wake of a 2022 incident where a Navy SEAL recruit died during training and was found with testosterone and other substances in his system. This tragedy led the Navy to initiate a drug-testing program for hormonal agents that promote muscle growth. Now, under Defense Secretary Mike Hegseth, the Pentagon is pushing a new initiative, while insisting it is not intended for 'artificial enhancement.'
Yet, the Department of Defense has failed to provide any meaningful details on the research or clinical guidelines behind this program. There is also a glaring omission: the policy does not clarify whether female personnel will be evaluated for estrogen-based therapy during perimenopause, perpetuating the military’s long history of gender inequity in healthcare access and support.
Medical experts point out that testosterone naturally declines with age and is associated with symptoms like low libido, mood changes, and weight gain. Current medical guidelines recommend testing only men with relevant symptoms and confirmed low levels on two separate morning blood draws. While the FDA has recently made it easier to prescribe testosterone products, the label still restricts use to men with hypogonadism, raising concerns about over-medicalization and pharmaceutical influence.
Representative Chrissy Houlahan, a Pennsylvania Air Force veteran and Democrat, criticized the Pentagon’s announcement, arguing that it reflects the influence of fringe online groups and fails to address the needs of all service members. She called for any testing to be available to both men and women, underscoring the urgent need for gender equity in military health policy.
This move comes alongside other recent Pentagon health policy changes, such as the repeal of the military flu-vaccine mandate earlier this year, highlighting the ongoing struggle for science-based, inclusive healthcare in the armed forces.